Faster Progression Of Lung Cancer May Be Indicated By High Levels Of Circulating DNARenée McGaw
Lung cancer is the leading cause of death among all malignancies due to rapid tumor progression and relapse; however, the underlying molecular mechanisms of tumor progression are unclear. In the present study, we identified ANKRD22 as a novel tumor-associated gene in non-small cell lung cancer (...
This study aims to reveal the potential effect of circNBPF10 on the malignant progression of lung cancer. The expression levels of circNBPF10 in lung cancer tissues and cell lines were detected via real-time quantitative PCR (RT-qPCR). The relationship between circNBPF10 expression and lung can...
Lung cancer is the most malignant tumor worldwide and the leading cause of cancer-related deaths with the highest mortality [1,2]. According to statistics, there are around over 1.8 million new cases and more than 1.6 million deaths resulted from lung cancer per year [2]. The insidious symp...
Lung cancer is one of the most important avoidable causes of death around the world, the most widespread carcinoma, with a very poor prognosis, and is the leading cause of cancer death in both developed and developing countries. We report morphological and biological behavior characteristics of a...
Lung cancer (LC) is the most frequent type of cancer worldwide and the leading cause of cancer mortality [1]. An essential factor in LC deaths is the invasion and metastasis of cancer cells through the circulation or lymphatic systems, Which is a significant cause of mortality in patients [...
The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol. 2014;50:1–6. [DOI] [PubMed] [PMC] 48.Paccione RJ, Miyazaki H, Patel V, Waseem A, Gutkind JS, Zehner ZE, et al. Keratin down-regulation in vimentin-positive cancer cells is ...
Reducing Lung Cancer Progression With Immunotherapy Rebecca Voelker, MSJ JAMA. 2018;319(13):1314. doi:10.1001/jama.2018.2928 Full Text The FDA has expanded its approval of durvalumab to include treating patients with unresectable stage III non–small cell lung cancer (NSCLC) whose tumors haven’...
Aberrant fucosylation observed in cancer cells contributes to an augmented release of fucosylated exosomes into the bloodstream, where miRNAs including miR-4732-3p hold promise as potential tumor biomarkers in our pilot study. However, the mechanisms und
TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways ArticleOpen access19 May 2022 NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity ...